VentriPoint Diagnostics Ltd V.VPT

RE:Ventripoint VMS+ Over Traditional MRI in Clinical Trials 🚀

[jopatclo]

Interesting comment 

Fiona Fitzgerald commented on this

Current selected sort order is Most relevantMost relevant

 

Fiona Fitzgerald(She/Her)• Following

Commercial Leader Nanomedicine Modality USCAN | advising biotechs & CDMOs on enabling LNP technologies from the bench to the clinic..

11h

Fantastic idea!

 

 

 

 

Like

 

Reply

Fiona Fitzgerald commented on this

 

Scott H.Scott H.• 3rd+• 3rd+IT Category ManagerIT Category Manager

1d • Edited • 1 day ago

Follow

Ventripoint ($VPTDF on the OTC) is only $.16/share today. Definitely going to be a game changer. Invest now! Don't say I didn't tell you.

Go check them out, do some research and let me know what you think.


#newstocks
#medtech
#gamechanger
#Ventripoint
#Angiopro
#cardiologic
#AscendCardiovcascular
#MedApp
#HealthcareInnovation
#MedicalAI
 #AugmentedReality

• 
• 

Venture Capital Fund, Startup, and Angel Investors ***Over 77,000 Members*** Meetings Every 60 DaysVenture Capital Fund, Startup, and Angel Investors ***Over 77,000 Members*** Meetings Every 60 DaysBart Hendriks • FollowingBart Hendriks • Following

2d • 2 days ago

Join

Revolutionizing Cardiac Diagnostics: The Cost-Effective and Inclusive Power of Ventripoint VMS+ Over Traditional MRI in Clinical Trials

In the realm of cardiac diagnostics, the Ventripoint VMS+ system emerges as a transformative tool, offering a unique blend of efficiency, cost-effectiveness, and patient inclusivity. Here’s why researchers and clinicians are opting for VMS+ over traditional cardiac MRI:

High Precision with Lower Costs: Traditional cardiac MRIs are known for their steep costs, encompassing expensive imaging equipment, specialized facilities, and prolonged testing times. In contrast, the Ventripoint VMS+ leverages standard echocardiography equipment to provide MRI-equivalent heart measurements, significantly reducing costs and making it a financially viable option for extensive clinical trials.

Enhanced Efficiency: The lengthy process required for MRI scans often leads to increased trial durations and higher costs. VMS+ simplifies cardiac assessment, enabling rapid, on-the-spot evaluations and accelerating the trial process.

Improved Patient Experience: The daunting nature of MRI scans can deter patient participation. The non-invasive and patient-friendly approach of the VMS+ increases comfort and compliance, which is crucial for successful clinical trials.

Magnetless Technology: The VMS+ system utilizes magnetless technology, making it a safe option for patients with pacemakers or other metallic implants who are typically excluded from MRI studies. This inclusion broadens the potential patient population for clinical trials, enhancing the diversity and applicability of research findings.

Reliable Data Collection: VMS+'s advanced algorithms deliver consistent and repeatable cardiac measurements, providing robust and reliable data essential for precise clinical analysis.

Dramatic Cost Reductions: Clinical trials can achieve significant cost reductions by integrating the VMS+ system. The savings come not only from eliminating expensive MRI scans but also from reduced patient attrition and more efficient data collection processes.

Accessibility and Portability: The VMS+'s portable nature expands its usability across diverse clinical settings, further driving down logistical costs and facilitating broader geographic reach in trials.

In clinical trials, where managing costs without compromising quality is paramount, the Ventripoint VMS+ offers an innovative, cost-effective, and inclusive solution. Connect with us to explore how VMS+ is reshaping cardiac diagnostics, making advanced technology accessible and affordable for a wider range of patients!

#Ventripoint #ClinicalTrials #CardiacHealth #Innovation #MedicalDevices #Cardiology #PacemakerSafe #CRO

• 1
• 1 comment

Like

Comment

 

Repost

 

 

 

Send

 

 

 

Add a comment…

Open Emoji Keyboard

 

Current selected sort order is Most relevantMost relevant

 

Fiona Fitzgerald(She/Her)• Following

Commercial Leader Nanomedicine Modality USCAN | advising biotechs & CDMOs on enabling LNP technologies from the bench to the clinic..

11h

Fantastic idea!

 

 

 

 

Like

 

Reply